A client with COPD is prescribed a daily scheduled maintenance drug by inhalation that decreases mucus production and airway resistance. Which drug will the nurse teach the client about?

Introduction: Chronic Obstructive Pulmonary Disease (COPD) management focuses on reducing airflow obstruction and minimizing bronchial secretions. Anticholinergics function as primary maintenance agents by antagonizing muscarinic receptors on bronchial smooth muscle and submucosal glands, effectively preventing acetylcholine-induced bronchoconstriction and excessive mucus production in the respiratory tract. A. Albuterol is a short-acting beta-2 agonist (SABA) primarily utilized as a "rescue" medication for acute bronchospasm. While it provides rapid bronchodilation, it is not the primary agent for daily maintenance to decrease mucus production, and its effects are transient rather than providing the sustained resistance reduction required for chronic stable COPD management. B. Montelukast is a leukotriene receptor antagonist administered orally rather than by inhalation. It is more commonly used in the prophylactic treatment of chronic asthma or allergic rhinitis. It does not provide the potent, direct bronchodilation or significant reduction in mucus volume typically achieved with inhaled muscarinic antagonists in COPD patients. C. IPRATROPIUM is an inhaled ANTICHOLINERGIC that blocks MUSCARINIC RECEPTORS, leading to bronchodilation. In COPD, it is specifically effective at DECREASING MUCUS secretions and reducing airway resistance. As a maintenance drug, it helps maintain airway patency and prevents the exacerbations associated with excessive cholinergic tone in the bronchioles. D. Salmeterol is a long-acting beta-2 agonist (LABA). While it is used for maintenance bronchodilation, its primary mechanism is the stimulation of beta receptors to relax smooth muscle. It does not possess the specific drying, anti-secretory properties of anticholinergics like ipratropium, which are crucial for managing the productive cough characteristic of COPD.